Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.

Vladimir A Karginov1, Adiamseged Yohannes, Tanisha M Robinson

  • 1Innovative Biologics, Inc., 10900 University Blvd., Manassas, VA 20110, USA. vak@innovbio.com

Bioorganic & Medicinal Chemistry
|September 20, 2005
PubMed
Summary

New research shows that blocking the pore formed by protective antigen can inhibit anthrax lethal toxin. Beta-cyclodextrin derivatives show promise as potential drug candidates for anthrax treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IFN-γ and IL-4 correlate with protection induced by an attenuated malaria vaccine.

NPJ vaccines·2025
Same author

Alteration of CD40 Protein Expression by Tyrosine Phosphorylation of the NF-κB p50 Subunit.

Chembiochem : a European journal of chemical biology·2025
Same author

Serine clamp of Clostridium perfringens binary toxin BECb (CPILEb)-pore confers cytotoxicity and enterotoxicity.

Communications biology·2025
Same author

Functionalized Nitrobenzothiadiazoles as Embedded Fluorescent Probes.

The Journal of organic chemistry·2025
Same author

Biological Regulation Studied <i>in Vitro</i> and <i>in Cellulo</i> with Modified Proteins.

Accounts of chemical research·2025
Same author

Enhancement of <i>N</i>-Methyl Amino Acid Incorporation into Proteins and Peptides Using Modified Bacterial Ribosomes and Elongation Factor P.

ACS chemical biology·2024

Area of Science:

  • Biochemistry
  • Microbiology
  • Drug Discovery

Background:

  • Anthrax toxin poses a significant threat, with combined antibiotic and antibody therapies showing promise.
  • The protective antigen component of anthrax toxin forms pores, crucial for its lethal activity.
  • Targeting this pore formation is a potential strategy for inhibiting anthrax toxin.

Purpose of the Study:

  • To investigate if blocking the protective antigen pore inhibits anthrax lethal toxin.
  • To identify novel inhibitors using structure-based drug design.
  • To evaluate beta-cyclodextrin derivatives for protective effects against anthrax lethal toxin.

Main Methods:

  • Structure-based drug design utilizing beta-cyclodextrin as a scaffold.
  • Synthesis of beta-cyclodextrin derivatives, specifically per-substituted aminoalkyl derivatives.

Related Experiment Videos

  • In vitro evaluation of derivative efficacy using RAW 264.7 cells challenged with anthrax lethal toxin.

    • Main Results:

    • Several beta-cyclodextrin derivatives demonstrated significant inhibitory activity against anthrax lethal toxin.
    • These derivatives provided protection to RAW 264.7 cells at low micromolar concentrations.
    • Per-substituted aminoalkyl derivatives were identified as particularly effective.

    Conclusions:

    • Blocking the protective antigen pore is a viable strategy to inhibit anthrax toxin.
    • Beta-cyclodextrin derivatives show potential as therapeutic agents for anthrax.
    • These findings support a structure-based drug discovery program for new anthrax treatments.